- Overview of Immunotherapy in Early-Stage NSCLC
- Evolving Role of Immunotherapy in Newly Diagnosed Advanced or Metastatic NSCLC
- Practical Considerations: Clinical Factors Influencing Response to Immune Checkpoint Inhibition
- What to Do After Progression on Immune Checkpoint Inhibitor Therapy: Future Directions
Mary Jo Fidler, MD
Rush University Medical Center
Scott Gettinger, MD
Professor of Internal Medicine (Medical Oncology)
Chief, Thoracic Medical Oncology
Yale Cancer Center
New Haven, Connecticut
The goal of this program is to improve the knowledge and competence of learners in immuno-oncology for the treatment of non-small cell lung cancer.
This educational program is intended for medical oncologists and other healthcare providers who treat patients with non-small-cell lung cancer.
- Select optimal first-line immune checkpoint inhibitor and chemotherapy combinations for patients with advanced or metastatic NSCLC
- Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor–based therapy in NSCLC
- Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy and in those who are ineligible for surgery or chemoradiation therapy
- Delineate the current biomarker testing recommendations for patients with stage III and IV NSCLC
- Incorporate investigational checkpoint inhibitors and clinical trial participation as part of clinical care strategies for NSCLC
- Appropriately mitigate and manage immune-related adverse events in patients receiving immune checkpoint inhibitors for the treatment of NSCLC
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.